N-[2-[二(羧甲基)氨基]-3-(4-乙氧基苯基)丙基]-N-[2-[二(羧甲基)氨基]乙基]-甘氨酸 | 135306-78-4

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: N-[2-[二(羧甲基)氨基]-3-(4-乙氧基苯基)丙基]-N-[2-[二(羧甲基)氨基]乙基]-甘氨酸
• 英文名称: 3,6,9-Triaza-3,6,9-tris(carboxymethyl)-4-(4-ethoxybenzyl)undecanedioic Acid
• 英文别名: Caloxetic acid；2-[[2-[bis(carboxymethyl)amino]-3-(4-ethoxyphenyl)propyl]-[2-[bis(carboxymethyl)amino]ethyl]amino]acetic acid
• CAS: 135306-78-4
• 化学式: C₂₃H₃₃N₃O₁₁
• 分子量: 527.529
• InChiKey: AQOXEJNYXXLRQQ-UHFFFAOYSA-N

物化性质

• 沸点：
  818.9±65.0 °C(Predicted)
• 密度：
  1.415±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -6.2
• 重原子数：
  37
• 可旋转键数：
  20
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.52
• 拓扑面积：
  205
• 氢给体数：
  5
• 氢受体数：
  14

反应信息

• 作为反应物：
  描述：

  N-[2-[二(羧甲基)氨基]-3-(4-乙氧基苯基)丙基]-N-[2-[二(羧甲基)氨基]乙基]-甘氨酸 以70的产率得到2-[[(2S)-2-[bis(carboxymethyl)amino]-3-(4-ethoxyphenyl)propyl]-[2-[bis(carboxymethyl)amino]ethyl]amino]acetic acid;gadolinium
  参考文献：
  名称：

  [EN] NOVEL PROCESS FOR THE PREPARATION OF GADOLINIUM COMPLEX OF (4S)-4-(4-ETHOXYBENZYL)-3,6,9-TRIS(CARBOXYLATOMETHYL)-3,6,9- TRIAZAUNDECANEDIOIC ACID DISODIUM (GADOXETATE DISODIUM)
  [FR] NOUVEAU PROCÉDÉ POUR LA PRÉPARATION DE COMPLEXE DE GADOLINIUM D'ACIDE (4S)-4-(4-ÉTHOXYBENZYL) -3,6,9-TRIS (CARBOXYLATOMÉTHYL)-3,6,9-TRIAZAUNDÉCANEDIOÏQUE DISODIQUE (GADOXATE DISODIQUE)

  摘要：

  本发明揭示了一种制备公式1的(4S)-4-(4-乙氧基苯基甲基)-3,6,9-三(羧基甲基)-3,6,9-三氮杂十二烷二酸二钠的钆配合物及其新型中间体的新工艺。

  公开号：

  WO2017208258A1
• 作为产物：
  描述：

  1-N-(2-aminoethyl)-3-(4-ethoxyphenyl)propane-1,2-diamine 以64的产率得到N-[2-[二(羧甲基)氨基]-3-(4-乙氧基苯基)丙基]-N-[2-[二(羧甲基)氨基]乙基]-甘氨酸
  参考文献：
  名称：

  一种钆塞酸二钠中间体的制备方法

  摘要：

  本发明公开了一种钆塞酸二钠中间体的制备方法，以化合物I或其盐为原料、直接与取代乙酸或其碱金属盐反应，一步合成关键中间体II或其盐形式。该技术路线新颖，收率高，操作简便，适合工业化大生产。

  公开号：

  CN103408444A

文献信息

• CHELATE NANOEMULSION FOR MRI
  申请人：Port Marc

  公开号：US20130309176A1

  公开（公告）日：2013-11-21

  The present invention relates to an oil-in-water nanoemulsion composition for MRI, comprising: an aqueous phase, representing 70% to 90% by weight of the composition, advantageously 75% to 85% and more advantageously from 78% to 82% a lipid phase comprising an oil, representing 9.5% to 29.5% by weight of the composition, advantageously 14% to 25% and more advantageously 17% to 21%, a surfactant at the interface between the aqueous and lipid phases, the surfactant comprising at least one amphiphilic paramagnetic metal chelate and optionally an amphiphilic lipid; the total content of surfactant by weight relative to the oil being between 4% and 10% and advantageously between 5% and 8%; the total content of surfactant by weight relative to the composition being between 0.35% and 2.95% and advantageously between 0.5% and 2%; the oil comprising at least 70%, advantageously at least 80%, advantageously at least 95% by weight and especially at least 97% of saturated C6-C18, advantageously C6-C14 and more advantageously C6-C10 fatty acids.

  本发明涉及一种用于磁共振成像的油包水纳米乳液组合物，包括： 水相，表示组合物重量的70%至90%，优选75%至85%，更优选78%至82%； 脂相包括一种油，表示组合物重量的9.5%至29.5%，优选14%至25%，更优选17%至21%； 表面活性剂位于水相和脂相之间的界面上，表面活性剂包括至少一种两性磁性金属螯合物和可选的两性脂质； 相对于油的重量，表面活性剂的总含量在4%至10%之间，优选在5%至8%之间； 相对于组合物的重量，表面活性剂的总含量在0.35%至2.95%之间，优选在0.5%至2%之间； 油包括至少70%，优选至少80%，优选至少95%的饱和C6-C18，优选C6-C14，更优选C6-C10脂肪酸。
• Bile acids conjugates with metal ion chelates and the use thereof
  申请人：——

  公开号：US20030113265A1

  公开（公告）日：2003-06-19

  Compounds able to chelate paramagnetic metal ions and the use thereof as contrast agents in the technique known as “Magnetic Resonance Imaging” (M.R.I.), which consist of at least two chelating agents conjugated via a multivalent linker group, to a bile acid.

  能够螯合顺磁性金属离子的化合物及其作为“磁共振成像”(M.R.I.)技术中的对比剂的应用，该化合物至少包括通过一个多价连接基团连接到胆酸的两个螯合剂。
• [EN] COMPOUNDS COMPRISING PARAMAGNETIC CHELATES ARRANGED AROUND A CENTRAL CORE AND THEIR USE IN MAGNETO RESONANCE IMAGING AND SPECTROSCOPY<br/>[FR] COMPOSÉS COMPRENANT DES CHÉLATES PARAMAGNÉTIQUES DISPOSÉS AUTOUR D'UN COER CENTRAL ET LEUR UTILISATION EN IMAGERIE ET SPECTROSCOPIE PAR RÉSONANCE MAGNÉTIQUE
  申请人：GE HEALTHCARE AS

  公开号：WO2009127715A1

  公开（公告）日：2009-10-22

  The present invention relates to novel compounds of formula (I) and (II), compositions comprising compounds of formula (II) and their use as contrast agents in magnetic resonance (MR) imaging (MRI) and MR spectroscopy (MRS).

  本发明涉及具有式(I)和(II)的新化合物，包含式(II)化合物的组合物，以及它们作为磁共振成像（MRI）和磁共振波谱（MRS）对比剂的用途。
• COMPOUNDS FOR THE DIAGNOSIS OF DISEASES ASSOCIATED WITH VCAM EXPRESSION
  申请人：Port Marc

  公开号：US20110200533A1

  公开（公告）日：2011-08-18

  The present invention relates to a compound of the following general formula (I): Signal-Linker-Peptide (I) in which: -Signal represents a signal entity; -Linker, which may or may not be present, represents a chemical bond, and -Peptide represents a peptide comprising a VCAM-targeting peptide, the VCAM-targeting peptide being chosen from the peptides of formula below and the functional equivalents thereof: a) X1-X2-X3-X4-X5-X6-X7-X8-X9 (1) (SEQ ID No. 1) where X1 is absent or chosen from cysteine and methionine; X2 chosen from asparagine and glutamine; X3 chosen from asparagine and glutamine; X4 chosen from serine and threonine; X5 chosen from lysine, arginine, histidine and ornithine; X6 chosen from serine and threonine; X7 chosen from histidine, arginine and lysine; X8 chosen from threonine and serine; X9 is absent or chosen from cysteine and methionine; preferably, the peptide CNNSKSHTC (SEQ ID No. 2) and the peptide NNSKSHT (SEQ ID No. 3); b) X10-X11-X12-X13-X14-X15-X16-X17-X18 (2) (SEQ ID No. 4) with X10 chosen from cysteine and methionine; X11 chosen from methionine and cysteine; X12 chosen from lysine, arginine and alanine; X13 chosen from threonine and serine; X14 chosen from aspartic acid and glutamic acid; X15 chosen from threonine and serine; X16 chosen from arginine, alanine and lysine; X17 chosen from leucine, isoleucine and valine; X18 chosen from cysteine and methionine; preferably, the peptide CMKTDTRLC (SEQ ID No. 5); and the pharmaceutically acceptable salts of these compounds of a) or of b).

  本发明涉及以下一般式(I)的化合物：Signal-Linker-Peptide (I)其中：- Signal代表信号实体；- Linker，可以存在也可以不存在，代表化学键；- Peptide代表包含VCAM靶向肽的肽，所述VCAM靶向肽从以下式的肽中选择，以及其功能等效物：a) X1-X2-X3-X4-X5-X6-X7-X8-X9 (1) (序列号1)，其中X1不存在或从半胱氨酸和蛋氨酸中选择；X2从天冬氨酸和谷氨酸中选择；X3从天冬氨酸和谷氨酸中选择；X4从丝氨酸和苏氨酸中选择；X5从赖氨酸、精氨酸、组氨酸和鸟氨酸中选择；X6从丝氨酸和苏氨酸中选择；X7从组氨酸、精氨酸和赖氨酸中选择；X8从苏氨酸和丝氨酸中选择；X9不存在或从半胱氨酸和蛋氨酸中选择；优选的肽为CNNSKSHTC (序列号2)和NNSKSHT (序列号3)；b) X10-X11-X12-X13-X14-X15-X16-X17-X18 (2) (序列号4)，其中X10从半胱氨酸和蛋氨酸中选择；X11从蛋氨酸和半胱氨酸中选择；X12从赖氨酸、精氨酸和丙氨酸中选择；X13从苏氨酸和丝氨酸中选择；X14从天冬氨酸和谷氨酸中选择；X15从苏氨酸和丝氨酸中选择；X16从精氨酸、丙氨酸和赖氨酸中选择；X17从亮氨酸、异亮氨酸和缬氨酸中选择；X18从半胱氨酸和蛋氨酸中选择；优选的肽为CMKTDTRLC (序列号5)；以及a)或b)中的这些化合物的药用盐。
• New agents for magnetic imaging method
  申请人：Bracco Imaging S.p.A.

  公开号：EP1369134A1

  公开（公告）日：2003-12-10

  The invention provides MRI detectable species of formula (I)         Dp-Sn-Nm     (I) wherein D is a MRI detectable moiety    S is a spacer    N is a molecule of a nutrient or pseudo-nutrient    n is 0 or an integer    m is an integer and    p is an integer. These compounds are useful for internalising into tumor cells an amount of the MRI detectable moiety that is distinguishably higher than the amount internalised in normal healthy cells thus allowing the diagnosis of tumors. Preferred compounds of formula (I) are those wherein D is the chelated complex of a paramagnetic metal ion. In this case when the paramagnetic metal ion is a neutron capture isotope, e.g. 157Gd, the new compounds can also be used for the treatment of the tumor, by selective irradiation of the tumor mass.

  该发明提供了一种具有以下式（I）的MRI可检测物种： Dp-Sn-Nm（I） 其中D是MRI可检测的基团 S是一个间隔物 N是一种营养物质或伪营养物质的分子 n为0或整数 m为整数 p为整数 这些化合物对于将MRI可检测的基团内化到肿瘤细胞中的数量高于内化到正常健康细胞中的数量是有用的，从而实现肿瘤的诊断。首选的式（I）化合物是D为顺磁金属离子的螯合络合物。在这种情况下，当顺磁金属离子是中子俘获同位素时，例如157Gd，这些新化合物也可以用于通过选择性照射肿瘤组织来治疗肿瘤。